| 【Company Research】Meituan (3690 HK) – More bullish on 2H22E recovery and profitability |
| 【Company Research】Tigermed (300347 CH) – Solid growth amid COVID-19 outbreaks |
| 【Company Research】Recbio Technology (2179 HK) – Smooth progress of core pipeline products |
| 【Company Research】Wingtech (600745 CH) – 2Q results in line; Maintain BUY |
| 【Company Research】Innolight (300308 CH) – Overseas data center demand to remain resilient in 2H22 |
| 【Company Research】Huitongda Network (9878 HK) – Resilient growth in 2H22 |
| 【Company Research】Innovent Biologics (1801 HK) – Fast expanding commercial product portfolio |
| 【Company Research】Zhejiang Jingsheng (300316 CH) – 2Q22 profit +1.4x YoY with strong cash flow; Raise earnings & TP on solid margin |
| 【Company Research】China Life (2628 HK) – New business volume growth turned positive in 2Q22 |
| 【Fixed Income Research】CARINC: Better than expected 1H22 results. Buy CARINC'24 as a carry play |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
